CN105407910B - 用于增强免疫应答的哺乳动物乳骨桥蛋白 - Google Patents

用于增强免疫应答的哺乳动物乳骨桥蛋白 Download PDF

Info

Publication number
CN105407910B
CN105407910B CN201480038124.7A CN201480038124A CN105407910B CN 105407910 B CN105407910 B CN 105407910B CN 201480038124 A CN201480038124 A CN 201480038124A CN 105407910 B CN105407910 B CN 105407910B
Authority
CN
China
Prior art keywords
years old
vaccine
opn
osteopontin
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480038124.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105407910A (zh
Inventor
安妮·施陶特·科维斯特加德
彼得·朗堡·魏谢
莎伦·多诺万
玛西亚·H·毛纳科·西格尔
莎拉·S·康斯托克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Publication of CN105407910A publication Critical patent/CN105407910A/zh
Application granted granted Critical
Publication of CN105407910B publication Critical patent/CN105407910B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
CN201480038124.7A 2013-07-05 2014-07-04 用于增强免疫应答的哺乳动物乳骨桥蛋白 Active CN105407910B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843185P 2013-07-05 2013-07-05
US61/843,185 2013-07-05
EP13175267 2013-07-05
EP13175267.7 2013-07-05
PCT/EP2014/064339 WO2015001092A1 (en) 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness

Publications (2)

Publication Number Publication Date
CN105407910A CN105407910A (zh) 2016-03-16
CN105407910B true CN105407910B (zh) 2019-12-03

Family

ID=48740972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480038124.7A Active CN105407910B (zh) 2013-07-05 2014-07-04 用于增强免疫应答的哺乳动物乳骨桥蛋白

Country Status (18)

Country Link
US (3) US9956283B2 (enExample)
EP (1) EP3016673B1 (enExample)
JP (1) JP6509833B2 (enExample)
KR (1) KR102307002B1 (enExample)
CN (1) CN105407910B (enExample)
AU (1) AU2014286123B2 (enExample)
BR (1) BR112016000067B1 (enExample)
CA (1) CA2916821C (enExample)
CL (1) CL2015003803A1 (enExample)
DK (1) DK3016673T3 (enExample)
EA (1) EA034654B1 (enExample)
ES (1) ES2656474T3 (enExample)
MX (1) MX369925B (enExample)
NZ (1) NZ715430A (enExample)
PH (1) PH12015502844B1 (enExample)
PL (1) PL3016673T3 (enExample)
PT (1) PT3016673T (enExample)
WO (1) WO2015001092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095082A1 (en) * 2018-04-25 2019-10-31 Health And Happiness (H&H) Hong Kong Limited Combinations of osteopontin and 2'-fucosyllactose for use as medicaments
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum
CN113424962A (zh) * 2020-09-21 2021-09-24 黑龙江飞鹤乳业有限公司 提高免疫力的营养组分、含有其的食品或保健品及其用途
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases
CN113475720B (zh) * 2021-06-15 2023-07-25 合生元（广州）健康产品有限公司 骨桥蛋白在增加肠道菌群多样性和增加肠道短链脂肪酸含量中的应用
CN118632706A (zh) 2022-01-31 2024-09-10 雀巢产品有限公司 包含骨桥蛋白（opn）的组合物
CN117337994A (zh) * 2023-10-11 2024-01-05 黑龙江飞鹤乳业有限公司 功能性组合物及该组合物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056404A1 (en) * 1997-06-11 1998-12-17 Acorda Therapeutics Cns neuroregenerative compositions and methods of use
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2013086459A1 (en) * 2011-12-07 2013-06-13 Arla Foods Amba Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
PT1244702E (pt) 2000-01-07 2006-08-31 Arla Foods Amba Processo para o isolamento da osteopontina do leite
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2003100007A2 (en) * 2002-05-24 2003-12-04 Schering-Plough Ltd. Eta-1 gene and methods for use
KR20130009866A (ko) * 2003-09-18 2013-01-23 아를라 푸즈 에이엠비에이 유아용 조제유
NZ546398A (en) * 2003-09-18 2009-03-31 Arla Foods Amba Infant formula
KR20090123115A (ko) * 2008-05-27 2009-12-02 한국생명공학연구원 오스테오폰틴을 유효성분으로 함유하는 자연살해세포분화용 조성물 및 이를 이용한 분화 방법
WO2012117119A1 (en) * 2011-03-03 2012-09-07 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056404A1 (en) * 1997-06-11 1998-12-17 Acorda Therapeutics Cns neuroregenerative compositions and methods of use
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2013086459A1 (en) * 2011-12-07 2013-06-13 Arla Foods Amba Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Also Published As

Publication number Publication date
JP6509833B2 (ja) 2019-05-08
WO2015001092A1 (en) 2015-01-08
MX369925B (es) 2019-11-25
EA201690057A1 (ru) 2016-07-29
EP3016673B1 (en) 2017-10-25
US9956283B2 (en) 2018-05-01
CL2015003803A1 (es) 2016-08-05
EP3016673A1 (en) 2016-05-11
USRE50281E1 (en) 2025-01-28
US20180289798A1 (en) 2018-10-11
MX2016000107A (es) 2016-06-07
DK3016673T3 (da) 2018-01-29
AU2014286123B2 (en) 2019-02-28
PH12015502844A1 (en) 2016-03-28
CA2916821C (en) 2023-10-03
KR102307002B1 (ko) 2021-10-05
PT3016673T (pt) 2018-01-30
BR112016000067B1 (pt) 2022-08-30
US20160136268A1 (en) 2016-05-19
PH12015502844B1 (en) 2016-03-28
CA2916821A1 (en) 2015-01-08
NZ715430A (en) 2022-01-28
KR20160030960A (ko) 2016-03-21
EA034654B1 (ru) 2020-03-03
PL3016673T3 (pl) 2018-04-30
ES2656474T3 (es) 2018-02-27
CN105407910A (zh) 2016-03-16
BR112016000067A2 (enExample) 2017-09-05
JP2016529217A (ja) 2016-09-23
US10772955B2 (en) 2020-09-15
AU2014286123A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
USRE50281E1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
Dowling et al. TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth
Wen et al. High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs
Ortiz-Andrellucchi et al. Immunomodulatory effects of the intake of fermented milk with Lactobacillus casei DN114001 in lactating mothers and their children
Shim et al. Elicitation of Th1/Th2 related responses in mice by chitosan nanoparticles loaded with Brucella abortus malate dehydrogenase, outer membrane proteins 10 and 19
CN103220921B (zh) 免疫佐剂
Saliganti et al. Consumption of probiotic Lactobacillus rhamnosus (MTCC: 5897) containing fermented milk plays a key role in development of the immune system in newborn mice during the suckling–weaning transition
Yang et al. The immunogenicity of Alum+ CpG adjuvant SARS-CoV-2 inactivated vaccine in mice
DK2066341T3 (en) PROCEDURE FOR INITIATING OR INDUCING AN IMMUNE RESPONSE
Richard et al. Breast milk conferred immunity to infants against COVID-19
CN114340666A (zh) 环二核苷酸的新用途
Graciliano et al. Impact of Maternal Exposure to SARS-CoV-2 on Immunological Components of Breast Milk
WO2022011271A2 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
JP6219728B2 (ja) Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物
Saliganti et al. Probiotics in the modulation of maternal–infant immunity: Implications for allergic diseases
İNECİ DETECTION OF SARS-COV-2 SPESIFIC IgA ANTIBODY IN THE HUMAN MILK OF COVID-19 VACCINATED LACTATING WOMEN
Orije The influence of maternal antibodies on the immune responses of term and preterm born infants
CN117222426A (zh) 基于控制细胞性免疫的新型方法的新型治疗和预防
Shunk Effect of bovine lactoferrin on T lymphocyte cell phenotype and function and the response to vaccination in the neonatal piglet
Lu Effects of supplemental osteopontin on intestinal development and serum antibody responses to rotavirus vaccination in piglets
Abd Wahab Investigation of the Coeliac Immunogenecity of Cereal Peptides and Their Quantification Using Monoclonal Antibodies
TW201137124A (en) Immunomodulatory compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant